Thomas Pfister
Overview
Explore the profile of Thomas Pfister including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
549
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cutolo M, Herrick A, Distler O, Becker M, Beltran E, Carpentier P, et al.
Arthritis Rheumatol
. 2016 Apr;
68(10):2527-39.
PMID: 27111549
Objective: To identify nailfold videocapillaroscopic features and other clinical risk factors for new digital ulcers (DUs) during a 6-month period in patients with systemic sclerosis (SSc). Methods: In this multicenter,...
12.
Rouquie D, Heneweer M, Botham J, Ketelslegers H, Markell L, Pfister T, et al.
Crit Rev Toxicol
. 2015 Jan;
45(2):172-83.
PMID: 25615431
Identification of the potential hazards of chemicals has traditionally relied on studies in laboratory animals where changes in clinical pathology and histopathology compared to untreated controls defined an adverse effect....
13.
Saller R, Kasper S, Dimpfel W, Savaskan E, Pfister T, Rostock M, et al.
Forsch Komplementmed
. 2014 Jul;
21 Suppl 1:2-18.
PMID: 25012282
No abstract available.
14.
Pfister T, Dolan D, Bercu J, Gould J, Wang B, Bechter R, et al.
Ann Occup Hyg
. 2014 Jun;
58(7):899-911.
PMID: 24958792
A literature review and analysis of inhalation bioavailability data for large therapeutic proteins was conducted in order to develop a practical estimate of the inhalation bioavailability of these drugs. This...
15.
Sitbon O, Delcroix M, Bergot E, Boonstra A, Granton J, Langleben D, et al.
Am Heart J
. 2014 Jan;
167(2):210-7.
PMID: 24439982
Background: Continuous infusion of epoprostenol is the treatment of choice in patients with pulmonary arterial hypertension in functional classes III to IV. However, this treatment's limitations include instability at room...
16.
Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man
Boess F, Bertinetti-Lapatki C, Zoffmann S, George C, Pfister T, Roth A, et al.
J Mol Endocrinol
. 2013 Mar;
50(3):325-36.
PMID: 23463748
Glucagon-like peptide 1 (GLP1) analogs have been associated with an increased incidence of thyroid C-cell hyperplasia and tumors in rodents. This effect may be due to a GLP1 receptor (GLP1R)-dependent...
17.
Park S, Speranza G, Piekarz R, Wright J, Kinders R, Wang L, et al.
Cancer Chemother Pharmacol
. 2013 Feb;
71(4):981-90.
PMID: 23404627
Purpose: A multi-cohort phase II study of fostamatinib, an oral multi-kinase inhibitor, was conducted to determine the response rate in patients with advanced colorectal (CRC), thyroid, non-small cell lung, head...
18.
Sargent E, Faria E, Pfister T, Sussman R
Regul Toxicol Pharmacol
. 2013 Jan;
65(2):242-50.
PMID: 23291300
Health-based limits for active pharmaceutical ingredients (API) referred to as acceptable daily exposures (ADEs) are necessary to the pharmaceutical industry and used to derive acceptance limits for cleaning validation purposes...
19.
Gocke E, Burgin H, Muller L, Pfister T
Toxicol Lett
. 2009 Oct;
190(3):254-65.
PMID: 19857796
In order to assess the risk of patients being exposed to an anti-AIDS medication contaminated with EMS we have performed in depth genotoxicity, general toxicity and DMPK investigations. The results...
20.
Muller L, Gocke E, Lave T, Pfister T
Toxicol Lett
. 2009 May;
190(3):317-29.
PMID: 19443141
Based on a production accident Viracept (nelfinavir mesilate) tablets, an HIV protease inhibitor supplied by Roche outside the US, Canada and Japan was contaminated with relatively high levels of ethyl...